After cardioversion for atrial fibrillation, how long should a patient remain on a direct‑acting oral anticoagulant (DOAC) if sinus rhythm is maintained?

Duration of DOAC Therapy After Cardioversion for Atrial Fibrillation

All patients must continue anticoagulation for at least 4 weeks after cardioversion, and then the decision to continue long-term anticoagulation is based on their thromboembolic risk profile (CHA₂DS₂-VASc score), NOT on whether they remain in sinus rhythm 1, 2.

The Critical Point: Sinus Rhythm Does Not Eliminate Stroke Risk

The maintenance of sinus rhythm after cardioversion does not change your anticoagulation decision. Here's why this matters:

• Minimum 4 weeks post-cardioversion: This is mandatory for all patients regardless of rhythm status, as cardioversion transiently impairs left atrial mechanical function even after electrical restoration of sinus rhythm 1, 2
• Beyond 4 weeks: Continue anticoagulation indefinitely if the patient has thromboembolic risk factors, even if perfect sinus rhythm is maintained 1, 2

Decision Algorithm After the Initial 4 Weeks

Continue DOAC Long-Term If:

• CHA₂DS₂-VASc score ≥2 in men or ≥3 in women: These patients require lifelong anticoagulation regardless of rhythm 2
• History of prior stroke/TIA/systemic embolism: Lifelong anticoagulation mandatory 1

May Consider Stopping DOAC If:

• CHA₂DS₂-VASc score = 0 in men or 1 in women: These low-risk patients may discontinue after 4 weeks 2

Intermediate Risk (Score = 1 in men):

• Generally favor continuing anticoagulation, but this requires shared decision-making weighing bleeding risk 2

Common Pitfalls to Avoid

The most dangerous misconception: Stopping anticoagulation because the patient "stayed in sinus rhythm." The 2024 ESC guidelines explicitly state that oral anticoagulation must "continue for at least 4 weeks in all patients after cardioversion and long-term in patients with thromboembolic risk factor(s) irrespective of whether sinus rhythm is achieved" 1.

Why? Because:

1. AF often recurs asymptomatically (silent AF)
2. The stroke risk is determined by the underlying cardiac substrate and comorbidities, not the rhythm at any given moment
3. Atrial mechanical dysfunction ("atrial stunning") persists for weeks after cardioversion even with normal electrical rhythm 3

Practical Implementation

• Week 0-4: All patients on therapeutic DOAC
• Week 4 assessment: Calculate CHA₂DS₂-VASc score
  • Score ≥2 (men) or ≥3 (women) → Continue indefinitely
  • Score 0 (men) or 1 (women) → May stop
  • Score 1 (men) → Individualize based on bleeding risk

DOACs are preferred over warfarin for this indication, as they provide equivalent or superior efficacy with better safety profiles 1, 2.